EFTR: eEFFECTOR Therapeutics, Inc. Price to Sales

Symbol and logo of brand eEFFECTOR Therapeutics, Inc. (EFTR)

eFFECTOR Therapeutics is advancing oncology pharmacology through partnerships with global medical centers to create immunotherapy synergy. This enables the development of a lung cancer treatment system by blocking protein synthesis, which is clearly reflected in the current P/S ratio, where the metric is fixed at 52.10. High demand for targeted drugs amid a shortage of solutions is expanding the company's client base.

eEFFECTOR (EFTR) - P/S Multiple from 07/04/2022 to 03/26/2024

Analytical breakdowns for eEFFECTOR Therapeutics Inc. (EFTR)

- share price and consensus valuation forecast:
Price Performance Chart effector.com|EFTR - Analyst Consensus Forecast
- market capitalization information:
Market Value eEFFECTOR|EFTR - Enterprise Value
- shareholders' equity book value data:
Share Book Value eEFFECTOR Therapeutics|EFTR - Book Capitalization|Market Capitalization to Net Assets effector.com|EFTR - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital eFFECTOR Therapeutics|EFTR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio eEFFECTOR|EFTR - Company Total Debt|Debt to Book Capital eEFFECTOR|EFTR - Company Long-Term Debt|Short-Term Debt eEFFECTOR Therapeutics|Intermediate Coverage Ratio effector.com
- earnings and valuation multiples indicators:
EFTR - Net Income|Expected Net Income eFFECTOR Therapeutics|EFTR - Price to Earnings Ratio|Market Cap to Future Earnings Ratio eEFFECTOR Therapeutics, Inc.|EFTR - PEG Multiple|Business Value to Operating Income Before Depreciation eEFFECTOR|EFTR - Operating profit EBITDA|Net earnings per one share for the last twelve months eEFFECTOR Therapeutics|EFTR - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months effector.com|EFTR - Earnings growth in current year|Earnings growth forecast for next year eFFECTOR Therapeutics
- issuer revenue and sales details:
EFTR - Company Revenue|Company Expected Revenue effector.com|EFTR - P/S Multiple|Market Cap to Future Revenue Ratio eEFFECTOR
Summary company analytics:effector.com
Mass-produced product of eFFECTOR Therapeutics

P/S measures the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of generated income. This revenue multiple trend reflects the sensitivity of capitalization to scaling rates, which is critical for eFFECTOR Therapeutics (EFTR) during the implementation of robotic screening and the automation of clinical data analysis for lung cancer therapy.

Competitors of eFFECTOR Therapeutics

AVBP (ArriVent BioPharma, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple LTRN (Lantern Pharma)|bioAffinity Technologies Inc. (BIAF) - Price to Sales